Losing Sheen: Apollo Education Group Inc (APOL), Infinity Pharmaceuticals Inc. (INFI), And Vitamin Shoppe Inc (VSI)

Posted by Lynn Eisler January 9, 2015 0 Comment 921 views

New York, NY – GDP INSIDER  – 01/09/2014.

Shares of for-profit education provider, Apollo Education Group Inc (NASDAQ:APOL), fell following its tepid 1Q2015 financial results and weak fiscal 2015 outlook. The company reported that its adjusted earnings declined more than 58% from the same quarter in the previous year. Revenue of $719.1 million fell short of the consensus estimate of $728 million and also missed the company’s own guidance of $720-$730 million. Additionally, revenue fell 15.2% from the previous year.

Apollo Education Group Inc (NASDAQ:APOL)’s downbeat 1Q earnings were attributed to a number of negative factors that included lower revenue and higher taxes.

The company slashed its fiscal 2015 top-line expectation to a range of $2.74-$2.80 billion. It originally forecast revenue in the range of $2.80-$2.85 billion. Apollo Education Group Inc (NASDAQ:APOL) also reduced its adjusted operating income outlook to between $250 and $290 million, yet it originally guided the column in the range of $300-$325 million.

Is APOL Going To Continue To Lose Value Or Will Things Start To Turn Around? Find Out What’s Next For APOL With A Free Trend Analysis Report

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) found itself among the top losing stocks following the failure of its lead drug, duvelisib, in a crucial test. The drug failed in a trial that sought to assess its performance in combating a condition known as rheumatoid arthritis, which affects more than 1.5 million people in the U.S. alone. Infinity Pharmaceuticals announced it would stop testing the drug for the indication following the failed study.

Duvelisib, the drug that failed a test for treatment rheumatoid arthritis, had previously also failed in another trial for allergic asthma.

Although Infinity Pharmaceuticals Inc. (NASDAQ:INFI) hinted at plans to abandon further test of duvelisib for rheumatoid arthritis, the company said the drug would still be test for various forms of blood cancer.

Could INFI Continue To Fall Or Will We Find Support In The Near Future? See What Is In The Cards For INFI With A Complementary Trend Analysis.

Vitamin Shoppe Inc (NYSE:VSI) received a bearish analyst research report that triggered a sell-off in its stock. Analysts at Bank of America Corp (NYSE:BAC) lost favor with the nutritional supplements company and downgraded it to “Underperform” from “Neutral”.

Meanwhile, Vitamin Shoppe Inc (NYSE:VSI) opened its first store location in Lancaster Country near Park City Center, another clear show that the company expects to boost its revenue stream. The company has store locations in the U.S., Canada and Panama.

Is VSI Going To Continue Selling Off Or Will Things Start Turning Around Soon? See What’s Next For VSI With A Free Trend Report

About UltimateStockAlerts

UltimateStockAlerts.com provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word ULTIMATE to 555888 from your cell phone.

UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.

Disclosure:  UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.

About Lynn Eisler

Lynn Eisler is a national news reporter focusing on economic issues, data analysis and the financial health of state and local governments. Lynn has been honored with the H.L. Mencken Award for Investigative Reporting, the Champion of Justice Award for reporting on the drug war, and the John Hancock Award for business reporting. Lynn was also a Knight Medical School Fellow at the University of Michigan.

View all post by Lynn Eisler Visit author's website

Write Your Comment